Cabernet Sauvig & Concord purple grape Juice: prom of non-amylo/Ho, Lap

这个互补和替代研究英才中心的总体目标是 药物在阿尔茨海默病中的应用是鉴定阿尔茨海默病中具有生物活性的葡萄多酚 Tg2576小鼠阿尔茨海默病AP神经病理模型的预防和/或治疗 认知能力下降。本申请中建议的研究基于我们的假设，即选择性 生物活性葡萄多酚对AD认知功能障碍发生和发展的保护作用 通过抑制淀粉样前体蛋白产生A/7多肽而恶化。我们将对此进行测试 假设通过使用生物引导的分馏方法来产生多酚制剂 赤霞珠和协和紫色葡萄汁的复杂性逐渐降低，将产生A0- 降低Tg2576 AD小鼠模型的活性。我们将继续探索ApMowering的疗效 多酚制剂延缓Tg2576阿尔茨海默病认知功能衰退的发生和发展 并阐明其作用机制。 本申请中建议的研究将补充本中心的其他研究项目 应用和阐明葡萄多酚钝化年龄相关性的一般机制 阿尔茨海默病，特别是在受轻度认知障碍影响的日益增长的人群中 AD的风险。拟议研究的结果可能会导致选择性葡萄衍生产品的开发。 多酚类化合物作为阿尔茨海默病临床检测的先导化合物

The overall objective of this Center of Excellence for Research on Complementary and Alternative Medicine in Alzheimer's disease application is to identify bioactive grape-derived polyhenols in AD prevention and/or therapy in the Tg2576 mouse model of Alzheimer's disease-type Ap neuropathology and cognitive deterioration. The proposed studies in this application are based on our hypothesize that selective bioactive grape-derived polyphenols protects against the onset and progression of AD-type cognitive deterioration by inhibiting the generation of A/7peptides from the amyloid precursor protein. We will test this hypothesis by using bio-guided fractionation methodologies to generate polyphenol preparations with progressively less complexity from Cabernet Sauvignon and from Concord purple grape juice that will exert A0- lowering activity in the Tg2576 AD mouse model. We will continue to explore the efficacy of ApMowering polyphenol preparations to attenuate the onset and progression of AD-type cognitive deterioration in Tg2576 mice and to clarify the mechanisms of action. The proposed studies in this application will complement the other Research Projects in this Center application and elucidate general mechanisms by which grape-derived polyphenolics may blunt age-related Alzheimer's disease, especially in a growing population affected by mild cognitive impairment that is at high risk for AD. Outcomes of the proposed studies will likely result in the development of selective grape-derived polyphenolic compounds as lead compounds for clinical testing in Alzheimer's disease